secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000950170-23-057481
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude prioritizes SMARCA2 and CDK9, partners with AbCellera on ADCs, reports Q3 net loss $30.6M
--------------------------------------------------------------------------------

- Q3 net loss $30.6M ($0.45/share); cash at $230.5M; cash runway into 2026.
- Prioritizing PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) for continued development.
- Discontinuation of MCL-1 (PRT1419) and CDK4/6 (PRT3645) programs; seeking partners for PRT3645.
- Entered partnership with AbCellera to develop precision ADCs using SMARCA payloads.
- Expects initial Phase 1 data for SMARCA2 and CDK9 in mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023057481/0000950170-23-057481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023057481/prld-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer